CTAG1B and melanoma: Target analysis from these trials revealed that cancer-testis antigens were frequently studied, with cancer-testis antigen 1B (CTAG1B, also known as NY-ESO-1) emerging as a prominent target in STS and showing notable relevance in NSCLC, esophageal cancer, melanoma, liver cancer, and ovarian cancer.